Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the Home-Based AIDS Care Program in Rural Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 3, 2008, Pages 304-311

  Buchacz, Kate ^a   Weidle, Paul J ^a   Moore, David ^b   Were, Willy ^b   Mermin, Jonathan ^b   Downing, Robert ^b   Kigozi, Aminah ^b   Borkowf, Craig B ^a   Ndazima, Vincent ^b   Brooks, John T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

Antiretroviral therapy; Cholesterol; High density lipoprotein; HIV; Lipid

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; NEVIRAPINE; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SUBSTITUTION; FEMALE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; UGANDA; BLOOD; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; HEALTH; HOME CARE; MIDDLE AGED; RISK FACTOR; STATISTICS; TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HOME CARE SERVICES; HUMANS; LIPIDS; MALE; MIDDLE AGED; NEVIRAPINE; RISK FACTORS; RURAL HEALTH; TIME FACTORS; TRIGLYCERIDES; UGANDA;

EID: 42449087791     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815e7453     Document Type: Article

References (35)

1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
2. Grover SA, Coupal L, Gilmore N, et al. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol. 2005;95:586-591.
3. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med. 2005;6:396-402.
4. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
5. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
6. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007;45:34-42.
7. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
8. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-647.
9. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:56-64.
10. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS. 2001;15:2407-2414.
11. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006 revision. Available at: http://www.who.int/hiv/pub/guidelines/adult/en/. Accessed August 30, 2007.
12. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:e19.
13. van Leth F, Hall DB, Lange JM, et al. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med. 2006;7:347-350.
14. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr. 2005;39:199-202.
15. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006;368:1587-1594.
16. Uganda Bureau of Statistics. Uganda National Household Survey 2002/2003: report on the socio-economic survey. Available at: http://www.ubos.org/ unhsII%20socio.pdf. Accessed August 6, 2007.
17. NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
18. Rosner B. Descriptive statistics. In: Fundamentals of Biostatistics. 3rd ed. Boston, MA: PWS-Kent Publishing Company; 1990:32-33.
19. Pauletto P, Puato M, Caroli MG, et al. Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania: the Lugalawa study. Lancet. 1996;348:784-788.
20. Njelekela MA, Negishi H, Nara Y, et al. Obesity and lipid profiles in middle aged men and women in Tanzania. East Afr Med J. 2002;79:58-64.
21. Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8:280-287.
22. Kerr SJ, Duncombe C, Avihingsanon A, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care. 2007;6:36-46.
23. Rose H, Woolley I, Hoy J, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism. 2006;55:90-95.
24. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993;94:515-519.
25. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
26. El Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114-121.
27. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
28. Carpentier A, Patterson BW, Uffelman KD, et al. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis. 2005;178:165-172.
29. Sankatsing RR, Wit FW, Pakker N, et al. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis. 2007;196:15-22.
30. Gil P, de Gorgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis. 2004;39:1024-1029.
31. Bonjoch A, Paredes R, Galvez J, et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr. 2005;39:313-316.
32. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-239.
33. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
34. Foulkes AS, Wohl DA, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3:e52.
35. Cowan LD, Wilcosky T, Criqui MH, et al. Demographic, behavioral, biochemical, and dietary correlates of plasma triglycerides. Lipid Research Clinics Program Prevalence Study. Arteriosclerosis. 1985;5:466-480.